Puma Biotechnology (NASDAQ:PBYI) has been given a $147.00 price objective by analysts at Credit Suisse Group in a research report issued on Monday. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Credit Suisse Group’s price target would indicate a potential upside of 56.47% from the stock’s current price.
Several other equities analysts have also recently commented on PBYI. Zacks Investment Research cut Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Monday, January 15th. Citigroup reaffirmed a “buy” rating and issued a $156.00 price target (up previously from $114.00) on shares of Puma Biotechnology in a report on Thursday, October 5th. JPMorgan Chase & Co. reaffirmed a “buy” rating and issued a $131.00 price target on shares of Puma Biotechnology in a report on Wednesday, October 4th. Stifel Nicolaus upped their price target on Puma Biotechnology from $110.00 to $130.00 and gave the company a “buy” rating in a report on Monday, October 2nd. Finally, ValuEngine cut Puma Biotechnology from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and nine have given a buy rating to the company. The company has an average rating of “Buy” and an average target price of $131.22.
Puma Biotechnology (PBYI) traded up $2.35 during trading on Monday, reaching $93.95. The company’s stock had a trading volume of 1,010,000 shares, compared to its average volume of 673,625. The firm has a market cap of $3,530.00, a PE ratio of -11.47 and a beta of 0.72. Puma Biotechnology has a 12-month low of $28.35 and a 12-month high of $136.90.
In other news, insider Charles R. Eyler sold 1,322 shares of the company’s stock in a transaction that occurred on Friday, December 1st. The stock was sold at an average price of $105.46, for a total value of $139,418.12. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 21.10% of the company’s stock.
Several hedge funds have recently added to or reduced their stakes in the company. Vanguard Group Inc. grew its stake in shares of Puma Biotechnology by 1.9% in the 2nd quarter. Vanguard Group Inc. now owns 2,474,644 shares of the biopharmaceutical company’s stock valued at $216,284,000 after purchasing an additional 45,735 shares during the period. Janus Henderson Group PLC grew its position in Puma Biotechnology by 1.8% during the 3rd quarter. Janus Henderson Group PLC now owns 1,890,901 shares of the biopharmaceutical company’s stock worth $226,435,000 after acquiring an additional 33,270 shares during the last quarter. BlackRock Inc. grew its position in Puma Biotechnology by 5.0% during the 2nd quarter. BlackRock Inc. now owns 1,830,342 shares of the biopharmaceutical company’s stock worth $159,973,000 after acquiring an additional 86,924 shares during the last quarter. Perceptive Advisors LLC grew its position in Puma Biotechnology by 26.0% during the 3rd quarter. Perceptive Advisors LLC now owns 923,820 shares of the biopharmaceutical company’s stock worth $110,627,000 after acquiring an additional 190,500 shares during the last quarter. Finally, Point72 Asset Management L.P. grew its position in Puma Biotechnology by 265.6% during the 3rd quarter. Point72 Asset Management L.P. now owns 482,200 shares of the biopharmaceutical company’s stock worth $57,743,000 after acquiring an additional 350,300 shares during the last quarter. Institutional investors own 95.86% of the company’s stock.
Puma Biotechnology Company Profile
Puma Biotechnology, Inc is a biopharmaceutical company that focuses on the development and commercialization of products for the treatment of cancer. The Company focuses on in-licensing the development and commercialization rights to over three drug candidates, including PB272 (neratinib (oral)), PB272 (neratinib (intravenous)) and PB357.
